Published: The New England Journal of Medicine
Date:
Authors: Aaron S Kelly 1 , Pernille Auerbach 1 , Margarita Barrientos-Perez 1 , Inge Gies 1 , Paula M Hale 1 , Claude Marcus 1 , Lucy D Mastrandrea 1 , Nandana Prabhu 1 , Silva Arslanian 1 , NN8022-4180 Trial Investigators
Abstract:
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.
Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-PĂ©rez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
Published: The New England Journal of Medicine
Date:
Authors: Vlado Perkovic 1 , Meg J Jardine 1 , Bruce Neal 1 , Severine Bompoint 1 , Hiddo J L Heerspink 1 , David M Charytan 1 , Robert Edwards 1 , Rajiv Agarwal 1 , George Bakris 1 , Scott Bull 1 , Christopher P Cannon 1 , George Capuano 1 , Pei-Ling Chu 1 , Dick de Zeeuw 1 , Tom Greene 1 , Adeera Levin 1 , Carol Pollock 1 , David C Wheeler 1 , Yshai Yavin 1 , Hong Zhang 1 , Bernard Zinman 1 , Gary Meininger 1 , Barry M Brenner 1 , Kenneth W Mahaffey 1 , CREDENCE Trial Investigators
Abstract:
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
Published: The Lancet Diabetes & Endocrinology
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Diabetes has been defined on the basis of different biomarkers, including fasting plasma glucose (FPG), 2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the effect of different diagnostic definitions on both the population prevalence of diabetes and the classification of previously undiagnosed individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health examination surveys in different regions.
Published: International journal of obesity and related metabolic disorders
Date:
Authors: R H Lustig 1 , S Sen, J E Soberman, P A Velasquez-Mieyer
Abstract:
Leptin resistance is a hallmark of obesity, but its etiology is unknown, and its clinical measurement is elusive. Leptin-sensitive subjects have normal resting energy expenditure (REE) at a low leptin concentration, while leptin-resistant subjects have a normal REE at a higher leptin concentration; thus, the ratio of REE:Leptin may provide a surrogate index of leptin sensitivity.